Cerebrolysin

Cerebrolysin is a biotechnologically produced peptide mixture obtained from purified porcine brain proteins through a standardized enzymatic breakdown process (Plosker & Gauthier, 2009, Drugs & Aging). It consists of low-molecular-weight peptides and free amino acids that are capable of crossing the blood-brain barrier to exert neurotrophic effects similar to endogenous growth factors like BDNF and GDNF (Masliah & Diez-Tejedor, 2012, Drugs of Today). The mixture supports neuronal survival, stimulates neurogenesis, and enhances synaptic plasticity, making it a therapeutic candidate for neurodegenerative and cerebrovascular disorders (Chen et al., 2019, Journal of Neural Transmission). It is clinically utilized for the treatment of Alzheimer's disease, vascular dementia, and recovery following ischemic stroke or traumatic brain injury (Ziganshina et al., 2020, Cochrane Database Syst Rev). Due to its heterogeneous nature, it does not target a single receptor but instead influences multiple pathways involved in neuroprotection and metabolic regulation within the central nervous system.

Other names

Porcine brain-derived peptide mixtureFPF 1070CerebrolysinumNeurotrophic peptide mixture

Cerebrolysin acts as a neurotrophic factor mimetic that promotes neuronal survival and template-driven repair. It modulates the PI3K/Akt signaling pathway, inhibits glycogen synthase kinase-3 beta (GSK-3β), and reduces the production of pro-inflammatory cytokines and free radicals (Chen et al., 2019, Journal of Neural Transmission). Additionally, it has been shown to decrease amyloid-beta deposition and tau hyperphosphorylation in preclinical models of Alzheimer's disease (Masliah & Diez-Tejedor, 2012, Drugs of Today).